|Description||HDAC-IN-2, a selective HDAC inhibitor, has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma. IC50: 4 nM and 76 nM for|
|Synonyms||HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat|
|Solubility||DMSO: ≥ 30 mg/mL|
|Application||HDAC-IN-2 is a selective HDAC inhibitor that has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Acetylon Pharmaceuticals|
RGFP 109 is a histone deacetylase (HDAC) inhibitor that has shown to reverse FXN gene silencing in short-term studies of Friedreich ataxia (FRDA) patient cells.
Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM.
ACY-738 is a potent and selective HDAC6 inhibitor with improved brain bioavailability. ACY-738 inhibits HDAC6 with low nanomolar potency and a selectivity of 60...
TCS HDAC6 20b
TCS HDAC6 20b is a histone deacetylase 6 (HDAC6) inhibitor. TCS HDAC6 20b inhibits HCT116 growth at a concentration of 5 µM in combination with taxol. It also i...
BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.
M344 is a potent HDAC inhibitor, which can also induced expression of the pro-apoptotic genes, Puma and Bax, together with the morphological features of apoptos...
Belinostat is a novel pan-HDAC inhibitor with IC50 of 27 nM, with activity demonstrated in cisplatin-resistant tumors. It inhibits the growth of tumor cells wit...
Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately...
CUDC-907 is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineo...
Oxamflatin, also known as Metacept-3, an aromatic sulfonamide derivative, is a cell-permeable, potent HDAC inhibitor (IC50= 15.7 nM) with antitumor effect.
Remodelin, a 2-thiazolylhydrazone derivative, is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10, which acetylates both histones ...
BRD 4354 is an HDAC5 and HDAC9 inhibitor (IC50 = 0.85 and 1.88 μM, respectively) displaying >20-fold selectivity for HDAC5/9 over HDAC1/2/3. It also weakly inhi...
Entinostat is a histone deacetylase (HDAC) inhibitor displaying antiproliferative and antineoplastic effects. Entinostat induces cyclin-dependent kinase inhibit...
Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs ...
TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor (IC50s= 59 nM, 60 nM, 26 nM and 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively), and ...
Valproic acid sodium salt (Sodium valpro
Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention o...
Resminostat is an inhibitor of histone deacetylase (HDAC) with IC50 values of 42.5nM, 50.1nM and 71.8nM, respectively against HDAC1, 3 and 6. As an inhibitor of...
MC 1742 is a novel and selective HDAC inhibitor with potential anticancer activity (IC50= 7, 20, 40, 100, 110 and 610 nM for HDAC6, HDAC3, HDAC10, HDAC1, HDAC2 ...
Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits his...